O Shaughnessy Asset Management LLC Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

O Shaughnessy Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 561 shares of the biopharmaceutical company’s stock after purchasing an additional 36 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $313,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Summit X LLC boosted its position in Regeneron Pharmaceuticals by 0.9% during the second quarter. Summit X LLC now owns 2,352 shares of the biopharmaceutical company’s stock worth $1,306,000 after purchasing an additional 20 shares in the last quarter. Cigna Investments Inc. New raised its stake in shares of Regeneron Pharmaceuticals by 0.6% during the 1st quarter. Cigna Investments Inc. New now owns 3,747 shares of the biopharmaceutical company’s stock worth $1,773,000 after buying an additional 21 shares during the last quarter. First Horizon Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 4.4% in the 1st quarter. First Horizon Advisors Inc. now owns 500 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 21 shares in the last quarter. Graypoint LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.3% in the 1st quarter. Graypoint LLC now owns 687 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 22 shares in the last quarter. Finally, Zions Bancorporation N.A. grew its stake in Regeneron Pharmaceuticals by 66.7% in the 1st quarter. Zions Bancorporation N.A. now owns 55 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 22 shares during the last quarter. Institutional investors and hedge funds own 82.31% of the company’s stock.

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Thursday, July 1st. The shares were sold at an average price of $564.50, for a total value of $56,450.00. Following the transaction, the director now owns 23,589 shares in the company, valued at $13,315,990.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider George Yancopoulos sold 80,000 shares of the firm’s stock in a transaction on Monday, June 21st. The shares were sold at an average price of $538.90, for a total transaction of $43,112,000.00. Following the completion of the transaction, the insider now directly owns 987,483 shares in the company, valued at approximately $532,154,588.70. The disclosure for this sale can be found here. Insiders have sold 389,040 shares of company stock valued at $240,594,454 over the last 90 days. 11.84% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals stock opened at $651.88 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $441.00 and a 1 year high of $686.62. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.04 and a current ratio of 3.57. The firm has a 50 day moving average price of $625.48 and a 200 day moving average price of $545.68. The company has a market cap of $69.72 billion, a price-to-earnings ratio of 11.71, a PEG ratio of 0.77 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 5th. The biopharmaceutical company reported $25.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $8.81 by $16.99. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $3.90 billion. Regeneron Pharmaceuticals had a net margin of 50.11% and a return on equity of 50.43%. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 51.91 EPS for the current year.

Several analysts have issued reports on REGN shares. UBS Group began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, September 9th. They issued a “buy” rating and a $763.00 price target on the stock. Benchmark upped their target price on Regeneron Pharmaceuticals from $636.00 to $727.00 and gave the company a “buy” rating in a research note on Monday, August 23rd. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $625.00 to $669.00 and gave the stock an “outperform” rating in a research report on Friday, August 6th. Barclays upped their price objective on Regeneron Pharmaceuticals from $675.00 to $705.00 and gave the company an “overweight” rating in a research report on Friday, August 6th. Finally, HC Wainwright increased their price objective on Regeneron Pharmaceuticals from $787.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $691.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Featured Story: What is a Market Correction?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.